视网膜母细胞瘤是一种罕见的发生在儿童早期的视网膜癌症。该疾病相对较少见，但具有侵略性，在儿童癌症中占约3％。治疗方法包括大量化疗药物的使用，这可能会导致多种副作用。因此，必须拥有安全有效的新疗法和适当的生理相关、无需动物的离体细胞培养模型，以便快速高效地评估潜在疗法方法。方法学：本研究重点关注使用蛋白质涂层鸡尾酒开发三级共培养模型，包括视网膜母细胞瘤、视网膜上皮和脉络膜内皮细胞，以在离体条件下复制这种眼部癌症。所得到的模型用于筛查药物毒性，基于视网膜母细胞瘤细胞的生长曲线，使用卡铂作为模型药物。此外，使用开发的模型评估了贝伐珠单抗和卡铂的组合，以降低卡铂浓度，从而减少其生理副作用。药物治疗对三级共培养的影响是通过视网膜母细胞瘤细胞凋亡率的增加进行评估。进一步发现，在降低包括展示波纹蛋白表达在内的血管生成信号的同时，该屏障性质较低。细胞因子水平的测量表明，通过药物组合治疗降低了炎症信号。这些发现验证了三级共培养视网膜母细胞瘤模型适用于评估抗视网膜母细胞瘤治疗，并且可以减轻动物试验的巨大负担，这是评估视网膜疗法使用的主要屏幕。本文章受版权保护。保留所有权利。

Retinoblastoma is a rare cancer of the retina that occurs during early childhood. The disease is relatively rare but aggressive, accounting for ∼3% of childhood cancers. Treatment modalities encompass the administration of large doses of chemotherapeutic drugs, which result in multiple side-effects. Therefore, it is essential to have safe and effective newer therapies and suitable physiologically relevant, alternative-to-animal, in vitro cell culture-based models to enable rapid and efficient evaluation of potential therapies METHODOLOGY: : This investigation was focused on the development of a triple co-culture model comprising retinoblastoma, retinal epithelium, and choroid endothelial cells, using a protein coating cocktail, to recapitulate this ocular cancer under in vitro conditions. This resulting model was used for screening drug toxicity, based on the growth profile of retinoblastoma cells, using carboplatin as the model drug. Further, a combination of bevacizumab and carboplatin was evaluated using the developed model, to lower the concentration of carboplatin and thereby reduce its physiological side-effects.The effect of drug treatment on the triple co-culture was assessed by increase in the apoptotic profile of retinoblastoma cells. Further, the barrier properties were found to be lower with a decrease in the angiogenetic signals that included expression of vimentin. Measurement of cytokine levels signified reduced inflammatory signals due to the combinatorial drug treatment.These findings validated that the triple co-culture retinoblastoma model was suitable for evaluating anti-retinoblastoma therapeutics and could thereby decrease the immense load on animal trials, which are the primary screens employed for evaluating retinal therapies. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.